XML 24 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Schedule of cash and cash equivalents
   December 31, 
   2019   2018 
Cash and cash equivalents  $16,350,237   $17,623,770 
Restricted cash   174,950    171,553 
Total cash, cash equivalents and restricted cash  $16,525,187   $17,795,323 
Schedule of marketable securities

 

 

December 31, 2019:

 

 

Amortized

Cost

  

Gross

Unrealized

Losses

  

Gross Unrealized

Gains

  

Fair Value

 
Money Market Funds and Cash Equivalents  $3,472,043   $-   $51   $3,472,094 
U.S. Government Agency Securities   2,691,091    (42)   869    2,691,918 
Corporate Securities   6,058,265    (1,438)   440    6,057,267 
Commercial Paper   3,234,583    (16)   405    3,234,972 
Subtotal   11,983,939    (1,496)   1,714    11,984,157 
Total December 31, 2019  $15,455,982   $(1,496)  $1,765   $15,456,251 
December 31, 2018:                    
Money Market Funds  $1,179,673   $-   $-   $1,179,673 
Total December 31, 2018  $1,179,673   $-   $-   $1,179,673 
Schedule of carrying and fair value of financial assets

December 31, 2019:  Carrying Value   Level 1   Level 2   Level 3 
Money Market Funds and Cash Equivalents  $3,472,094   $3,472,094   $-   $- 
U.S. Government Agency Securities   2,691,918    2,691,918    -    - 
Corporate Securities   6,057,267    -    6,057,267    - 
Commercial Paper   3,234,972    -    3,234,972    - 
Subtotal   11,984,157    2,691,918    9,292,239    - 
Total December 31, 2019  $15,456,251   $6,164,012   $9,292,239   $- 
December 31, 2018:                    
Money Market Funds  $1,179,673   $1,179,673   $-   $- 
Total December 31, 2018  $1,179,673   $1,179,673   $-   $- 
Schedule of segment and geographic information

   December 31, 
   2019   2018 
Reported revenues  $283,266   $429,327 
Revenues attributable to European and Mideast operations, which are based in Germany   274,443    420,973 
Total assets   29,475,910    18,825,914 
Total assets located in the United States, with the remainder in the European Union  $28,919,276   $18,154,463 
Schedule of inventories

   December 31, 
   2019   2018 
Raw materials  $6,893   $71,275 
Work in process   -    86,957 
Finished goods   461,735    373,283 
Inventory reserve   (130,163)   (103,000)
Total  $338,465   $428,515 
Schedule of property and equipment

Description   Estimated Useful Life  
Office equipment and furniture   5 years  
Leasehold improvements   5 years  
Computer equipment   5 years  
Computer software   3 years  
Schedule of accrued expenses

   December 31, 
   2019   2018 
Professional and consulting fees  $214,777   $258,352 
Accrued payroll and payroll taxes   1,287,047    1,102,143 
Clinical trial related   2,435,953    3,408,032 
Manufacturing development related   806,032    210,577 
Product development   -    49,200 
Other   56,677    137,920 
Total  $4,800,486   $5,166,224 
Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share

   Number of Shares of Common Stock Issuable At 
   December 31, 
   2019   2018 
Series C non-voting preferred stock   104,000    508,000 
Series D non-voting preferred stock   -    295,848 
Series E voting preferred stock   391,953    391,953 
Series F non-voting preferred stock   -    2,469,136 
Series G voting preferred stock   5,560,137    - 
Shares issuable upon conversion of convertible debt   -    1,000,000 
Restricted stock units   2,490    5,817 
Shares issuable for payment of deferred board compensation   33,597    28,578 
Shares underlying outstanding warrants   341,328    3,319,003 
Shares underlying outstanding stock options   1,376,394    1,011,265 
Total potentially dilutive shares   7,809,899    9,029,600